Cargando…

Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes

BACKGROUND: Risk stratification of patients with prediabetes is an unmet clinical need. Here, we examine the utility of subclinical myocardial necrosis assessed by high-sensitivity cardiac troponin T (hs-cTnT) in predicting health outcomes in stable subjects with prediabetes. METHODS: hs-cTnT was an...

Descripción completa

Detalles Bibliográficos
Autores principales: Witkowski, Marco, Wu, Yuping, Hazen, Stanley L., Tang, W. H. Wilson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379781/
https://www.ncbi.nlm.nih.gov/pubmed/34419046
http://dx.doi.org/10.1186/s12933-021-01365-9
_version_ 1783741077375680512
author Witkowski, Marco
Wu, Yuping
Hazen, Stanley L.
Tang, W. H. Wilson
author_facet Witkowski, Marco
Wu, Yuping
Hazen, Stanley L.
Tang, W. H. Wilson
author_sort Witkowski, Marco
collection PubMed
description BACKGROUND: Risk stratification of patients with prediabetes is an unmet clinical need. Here, we examine the utility of subclinical myocardial necrosis assessed by high-sensitivity cardiac troponin T (hs-cTnT) in predicting health outcomes in stable subjects with prediabetes. METHODS: hs-cTnT was analyzed by a high-sensitivity assay (Roche 5th generation) in 2631 stable subjects with prediabetes (HbA1c 5.7–6.4% or fasting glucose 100–125 mg/dL without previous diagnosis of diabetes or glucose-lowering therapy) who underwent elective coronary angiography for cardiac evaluation, and followed for major adverse cardiac events (MACE; death, myocardial infarction, stroke) over 3 years and all-cause mortality over 5 years. RESULTS: In our study cohort, hs-cTnT was highly prevalent with a median level of 13 ng/L (interquartile range 8.2–21.6 ng/L). Hs-cTnT was independently associated with incident MACE at 3 years (Q4 vs. Q1 adjusted hazard ratio (HR) 2.42 [95% CI 1.69–3.46], P < 0.001) and 5-year mortality (adjusted HR 3.8 [95% CI 2.55–5.67], P < 0.001). This association remained significant in all subsets after adjustment for traditional risk factors and multiple factors known to increase hs-cTnT levels. Moreover, hs-cTnT independently predicted event risk in primary prevention subjects (n = 557, HR 5.46 [95% CI 1.50–19.89), p < 0.01) for MACE; HR 9.53 [95% CI 2.08–43.73] for all-cause mortality) and secondary prevention subjects (n = 2074, HR 1.86 [95% CI 1.31–2.66], P < 0.001 for MACE; and 2.7 [95% CI 1.79–4.08), P < 0.001 for all-cause mortality). CONCLUSIONS: In stable prediabetic subjects, the presence of subclinical myocardial necrosis as detected by hs-cTnT portends heightened long-term adverse cardiovascular event risk. Hs-cTnT levels may help to stratify risk and improve clinical decision making in patients with prediabetes. Trial registration ClinicalTrials.gov Identifier: NCT00590200. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01365-9.
format Online
Article
Text
id pubmed-8379781
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83797812021-08-23 Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes Witkowski, Marco Wu, Yuping Hazen, Stanley L. Tang, W. H. Wilson Cardiovasc Diabetol Original Investigation BACKGROUND: Risk stratification of patients with prediabetes is an unmet clinical need. Here, we examine the utility of subclinical myocardial necrosis assessed by high-sensitivity cardiac troponin T (hs-cTnT) in predicting health outcomes in stable subjects with prediabetes. METHODS: hs-cTnT was analyzed by a high-sensitivity assay (Roche 5th generation) in 2631 stable subjects with prediabetes (HbA1c 5.7–6.4% or fasting glucose 100–125 mg/dL without previous diagnosis of diabetes or glucose-lowering therapy) who underwent elective coronary angiography for cardiac evaluation, and followed for major adverse cardiac events (MACE; death, myocardial infarction, stroke) over 3 years and all-cause mortality over 5 years. RESULTS: In our study cohort, hs-cTnT was highly prevalent with a median level of 13 ng/L (interquartile range 8.2–21.6 ng/L). Hs-cTnT was independently associated with incident MACE at 3 years (Q4 vs. Q1 adjusted hazard ratio (HR) 2.42 [95% CI 1.69–3.46], P < 0.001) and 5-year mortality (adjusted HR 3.8 [95% CI 2.55–5.67], P < 0.001). This association remained significant in all subsets after adjustment for traditional risk factors and multiple factors known to increase hs-cTnT levels. Moreover, hs-cTnT independently predicted event risk in primary prevention subjects (n = 557, HR 5.46 [95% CI 1.50–19.89), p < 0.01) for MACE; HR 9.53 [95% CI 2.08–43.73] for all-cause mortality) and secondary prevention subjects (n = 2074, HR 1.86 [95% CI 1.31–2.66], P < 0.001 for MACE; and 2.7 [95% CI 1.79–4.08), P < 0.001 for all-cause mortality). CONCLUSIONS: In stable prediabetic subjects, the presence of subclinical myocardial necrosis as detected by hs-cTnT portends heightened long-term adverse cardiovascular event risk. Hs-cTnT levels may help to stratify risk and improve clinical decision making in patients with prediabetes. Trial registration ClinicalTrials.gov Identifier: NCT00590200. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12933-021-01365-9. BioMed Central 2021-08-21 /pmc/articles/PMC8379781/ /pubmed/34419046 http://dx.doi.org/10.1186/s12933-021-01365-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Original Investigation
Witkowski, Marco
Wu, Yuping
Hazen, Stanley L.
Tang, W. H. Wilson
Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes
title Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes
title_full Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes
title_fullStr Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes
title_full_unstemmed Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes
title_short Prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin T in patients with prediabetes
title_sort prognostic value of subclinical myocardial necrosis using high-sensitivity cardiac troponin t in patients with prediabetes
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379781/
https://www.ncbi.nlm.nih.gov/pubmed/34419046
http://dx.doi.org/10.1186/s12933-021-01365-9
work_keys_str_mv AT witkowskimarco prognosticvalueofsubclinicalmyocardialnecrosisusinghighsensitivitycardiactroponintinpatientswithprediabetes
AT wuyuping prognosticvalueofsubclinicalmyocardialnecrosisusinghighsensitivitycardiactroponintinpatientswithprediabetes
AT hazenstanleyl prognosticvalueofsubclinicalmyocardialnecrosisusinghighsensitivitycardiactroponintinpatientswithprediabetes
AT tangwhwilson prognosticvalueofsubclinicalmyocardialnecrosisusinghighsensitivitycardiactroponintinpatientswithprediabetes